866-997-4948(US-Canada Toll Free)

Global Hemophilia Drugs Market 2016-2020

Published By :

Technavio

Published Date : Oct 2016

Category :

Diseases & Conditions

No. of Pages : 84 Pages

About Hemophilia

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Technavios analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Baxalta
Bayer
CSL Behring
Novo Nordisk
Pfizer

Other prominent vendors
Alnylam Pharmaceuticals
Amarna Therapeutics
Asklepios BioPharmaceutical
Biogen
BioMarin
Catalyst Bioscience
Chiesi Farmaceutici
Dimension Therapeutics
Emergent BioSolutions
F. Hoffmann-La Roche
Grifols, Kedrion Biopharma
Octapharma
rEVO Biologics
OPKO Biologics
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
UniQure Biopharma.

Market driver
Focus on prophylactic treatment
For a full, detailed list, view our report

Market challenge
Low diagnosis rate
For a full, detailed list, view our report

Market trend
Increase in technological innovations
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.



Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Pipeline portfolio
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation by type of disease
Global hemophilia A drugs market
Global hemophilia inhibitors treatment market
Global hemophilia B drugs market
Global von Willebrand disease treatment market
PART 08: Market segmentation by type of therapy
Recombinant therapies
Plasma-derived therapies
PART 09: Market segmentation by type of disease management
Prophylaxis
On-demand therapy
Inhibitor therapy
PART 10: Geographical segmentation
Hemophilia drugs market in Americas
Hemophilia drugs market in EMEA
Hemophilia drugs market in APAC
PART 11: Market drivers
Focus on prophylactic treatment
Drugs with prolonged action
Improved diagnostic procedures
PART 12: Impact of drivers
PART 13: Market challenges
Low diagnosis rate
High entry barriers
Cost-intensive complex treatment
PART 14: Impact of drivers and challenges
PART 15: Market trends
Increase in technological innovations
Development of gene therapy products
Centralized buyers should pave the way to increased penetration
PART 16: Vendor landscape
Competitive scenario
Other prominent vendors
PART 17: Key vendor analysis
Baxalta
Bayer
CSL Behring
Novo Nordisk
Pfizer
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria for global hemophilia drugs market 2015
Exhibit 04: Key customer segments of hemophilia drugs market
Exhibit 05: Pipeline portfolio: Global hemophilia drugs market
Exhibit 06: Pipeline share of major companies
Exhibit 07: Global hemophilia drugs market snapshot: Developed and emerging markets 2015
Exhibit 08: Global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 09: Impact of factors affecting the market 2015 and 2020
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global hemophilia drugs market by disease type based on revenue 2015
Exhibit 12: Global hemophilia drugs market segmentation growth lifecycle analysis
Exhibit 13: Global hemophilia drugs market by disease type 2015-2020
Exhibit 14: Global hemophilia A drugs market 2015-2020 ($ billions)
Exhibit 15: Global hemophilia inhibitors treatment market 2015-2020 ($ billions)
Exhibit 16: Global hemophilia B drugs market 2015-2020 ($ billions)
Exhibit 17: Global von Willebrand disease treatment market 2015-2020 ($ millions)
Exhibit 18: Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015
Exhibit 19: Global hemophilia drugs market by type of therapy 2015-2020
Exhibit 20: Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 21: Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 22: Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015
Exhibit 23: Global hemophilia drugs market by geography 2015-2020
Exhibit 24: Percentage share of global hemophilia drugs market by geography 2015 and 2020
Exhibit 25: Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 26: Global share of hemophilia drugs market by geography 2015
Exhibit 27: Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 28: Global hemophilia drugs market: Country analysis based on revenue and growth rate
Exhibit 29: Opportunity analysis of hemophilia drugs market in Americas
Exhibit 30: Hemophilia drugs market in Americas 2015-2020 ($ billions)
Exhibit 31: Opportunity analysis of hemophilia drugs market in EMEA
Exhibit 32: Hemophilia drugs market in EMEA 2015-2020 ($ billions)
Exhibit 33: Opportunity analysis of hemophilia drugs market in APAC
Exhibit 34: Hemophilia drugs market in APAC 2015-2020 ($ billions)
Exhibit 35: Impact of drivers
Exhibit 36: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Gene therapies under development for hemophilia
Exhibit 39: Market share of vendors 2015
Exhibit 40: Geographical presence of key vendors
Exhibit 41: Competitive scenario of global hemophilia drugs market vendors 2015-2020
Exhibit 42: Baxalta: Strength assessment
Exhibit 43: Baxalta: Strategy assessment
Exhibit 44: Baxalta: Opportunity assessment
Exhibit 45: Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 46: Bayer: Strength assessment
Exhibit 47: Bayer: Strategy assessment
Exhibit 48: Bayer: Opportunity assessment
Exhibit 49: Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions)
Exhibit 50: CSL Behring: Strength assessment
Exhibit 51: CSL Behring strategy assessment
Exhibit 52: CSL Behring opportunity assessment
Exhibit 53: CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions)
Exhibit 54: Novo Nordisk: Strength assessment
Exhibit 55: Novo Nordisk: Strategy assessment
Exhibit 56: Novo Nordisk: Opportunity assessment
Exhibit 57: Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 58: Pfizer: Strength assessment
Exhibit 59: Pfizer: Strategy assessment
Exhibit 60: Pfizer: Opportunity assessment
Exhibit 61: Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *